Gilead Sciences (GILD) Non Operating Interest Expenses (2009 - 2026)

On a trailing twelve-month basis, Gilead Sciences' Non Operating Interest Expenses was $1.01 billion through Sep 30, 2026, down 0.8% year-over-year; for FY2025, it came in at $1.02 billion, up 4.8% from FY2024.

• Non Operating Interest Expenses has now increased for three consecutive years, with a five-year compound annual growth rate of 0.8% (FY2020 to FY2025).
• In earlier years, Non Operating Interest Expenses was $977 million in FY2024 (+3.5%), $944 million in FY2023 (+1.0%), $935 million in FY2022 (-6.6%) and $1 billion in FY2021 (+1.7%).
• The Q3 2026 figure marks the highest quarterly Non Operating Interest Expenses since Q1 2018.
• Compared with a year earlier, Non Operating Interest Expenses was higher in five of the last eight quarters, with growth averaging 1.6%.
• The best year-over-year quarter for Non Operating Interest Expenses over five years was Q4 2023 (growth of 11.5%); the worst was Q4 2021 (a decline of 10.9%).
• Per Business Quant data, GILD's Non Operating Interest Expenses in the three quarters before Q3 2026 was $247 million (Q2 2026), $240 million (Q1 2026) and $255 million (Q4 2025).